Skip to main content
OpenTrials
Completed

NCT Number: NCT05748587

Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in Ischemic Stroke

This observational study aims to detect levels of iron, alpha-synuclein, and soluble lymphocyte activation gene 3 in acute ischemic stroke patients. And to see expressions of iron, alpha-synuclein, and lymphocyte activation gene 3 in the brain tissue of ischemic rats. The main questions it aims to answer are:

* Is there an association between iron and alpha-synuclein accumulation in ischemic stroke? * Is there any change in soluble lymphocyte activation gene levels in ischemic stroke and if these levels are related to stroke severity and infarction size? . Can soluble lymphocyte activation gene levels be used as an early biomarker to diagnose ischemic stroke?

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Brain Ischemia Brain Diseases Cardiovascular Diseases Central Nervous System Diseases Cerebrovascular Disorders Nervous System Diseases Vascular Diseases

Age range

50 year–70 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Aswan University Hospital

Aswān, 81528, Egypt

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients at the age between 50-70 years.
  • Patients having neurological symptoms of acute ischemic stroke.

Exclusion criteria

  • Patients with acute hemorrhagic stroke.
  • Patients with Parkinson's disease (PD).
  • Patients with dementia, and Alzheimer's disease.
  • Patients with any type of malignancy.
  • Patients with central nervous system infection.

Treatment and study plan

Serum Iron

Diagnostic Test

Serum iron levels in study groups

RBCs Alpha-synuclein

Diagnostic Test

α-syn levels in RBCs

Other names: α-syn

Serum Soluble lymphocyte activation gene

Diagnostic Test

sLAG-3 in the serum of study groups

Other names: sLAG-3

Brain computed tomography

Radiation

Brain CT of patients after admission

Other names: CT

Brain Iron

Diagnostic Test

Iron in brain homogenate of rats

Brain Alpha-synuclein

Diagnostic Test

α-syn expression in rat's brain

Other names: α-syn

Brain lymphocyte activation gene

Diagnostic Test

LAG-3 expression in rat's brain

Other names: LAG-3

Deferoxamine

Drug

intramuscular deferoxamine (200 mg/kg) injection to rats

Primary outcomes

  1. Iron levels

    Time frame: 6 months

    Serum iron levels in ischemic patients and control

  2. Alpha-synuclein levels

    Time frame: 6 months

    Alpha-synuclein levels in RBCs in ischemic patients and control

  3. Levels of Soluble lymphocyte activation gene-3

    Time frame: 6 months

    Serum soluble lymphocyte activation gene-3 in ischemic patients and control

  4. levels of iron, alpha-synuclein, and soluble lymphocyte activation in relation to stroke severity and infarction size

    Time frame: 6 months

    stroke severity will be evaluated by the National Institutes of Health Stroke Scale (NIHSS) and size of infarction will be detected by brain CT

  5. Iron levels in brain of rats

    Time frame: 2 months

    Iron levels in brain homogenate of rats in the three rat groups

  6. Levels of Alpha-synuclein expression in brain of rats

    Time frame: 2 months

    Alpha-synuclein expression in brain of rats in different groups

  7. Levels of Lymphocyte activation gene-3 expression in brain of rats

    Time frame: 2 months

    lymphocyte activation gene-3 expression in brain of rats in different groups

Sponsors and collaborators

Lead sponsor

Aswan University Hospital

Other

Registry information

Official study title

Role of Iron, Alpha-Synuclein, and Lymphocyte-activation Gene-3 in the Pathophysiology of Ischemic Stroke in Human and Albino Rats

Important dates

Study start
2023
Primary completion
2024
Study completion
2024
First posted
Feb 28, 2023
Registry last updated
Jun 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.